Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3018694rdf:typepubmed:Citationlld:pubmed
pubmed-article:3018694lifeskim:mentionsumls-concept:C0031330lld:lifeskim
pubmed-article:3018694lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:3018694lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:3018694lifeskim:mentionsumls-concept:C0017130lld:lifeskim
pubmed-article:3018694lifeskim:mentionsumls-concept:C0001455lld:lifeskim
pubmed-article:3018694lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:3018694lifeskim:mentionsumls-concept:C1152797lld:lifeskim
pubmed-article:3018694lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:3018694lifeskim:mentionsumls-concept:C0079411lld:lifeskim
pubmed-article:3018694pubmed:dateCreated1986-10-23lld:pubmed
pubmed-article:3018694pubmed:abstractTextWe measured 125I-secretin binding to membranes prepared from rat fundic glands and compared the abilities of natural and synthetic secretin (SN) analogs to inhibit 125I-secretin binding and to activate the cAMP generating system in glandular and subcellular preparations from the fundus and antrum. The natural peptides structurally related to porcine secretin (pSN) included: chicken secretin (cSN), vasoactive intestinal peptide (VIP), porcine peptide with N-terminal histidine and C-terminal isoleucine amide (PHI), helodermin, growth hormone releasing factors isolated from the rat hypothalamus (rhGRF-43, rhGRF-29) or from a human pancreatic tumour (hpGRF-40). These peptides inhibited the binding of 125I-secretin to rat fundic membranes: pSN greater than cSN greater than PHI, VIP and activated the cAMP generating system in fundic glands, according to the following order of potency; pSN greater than cSN greater than PHI, VIP greater than rhGRF-29 greater than rhGRF-43. Porcine peptide with N-terminal tyrosine and C-terminal tyrosine (PYY), GIP, SOM and hpGRF-40 were inactive. Structural requirements for secretin receptor activity were evaluated with four synthetic secretin analogs corresponding to porcine secretin substituted at the N-terminal end by sequence portion of VIP, GIP, GLU and SOM: Ala4-Val5-SN(VIP-SN); Tyr1-Ala2-Glu3-SN (GIP-SN); Gln3-SN (GLU-SN) and Phe1-Phe1-Trp3-Lys4-SN (SOM-SN). The relative potencies of the analogs in fundic and antral preparations were: pSN greater than VIP-SN greater than VIP, GIP-SN greater than GLU-SN greater than SOM-SN for 125I-secretin displacement and cAMP production (glandular cAMP generation and adenylate cyclase activation).(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:3018694pubmed:languageenglld:pubmed
pubmed-article:3018694pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3018694pubmed:citationSubsetIMlld:pubmed
pubmed-article:3018694pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3018694pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3018694pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3018694pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3018694pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3018694pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3018694pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3018694pubmed:statusMEDLINElld:pubmed
pubmed-article:3018694pubmed:issn0196-9781lld:pubmed
pubmed-article:3018694pubmed:authorpubmed-author:WünschEElld:pubmed
pubmed-article:3018694pubmed:authorpubmed-author:RosselinGGlld:pubmed
pubmed-article:3018694pubmed:authorpubmed-author:BatailleDDlld:pubmed
pubmed-article:3018694pubmed:authorpubmed-author:MoroderLLlld:pubmed
pubmed-article:3018694pubmed:authorpubmed-author:VauclinNNlld:pubmed
pubmed-article:3018694pubmed:authorpubmed-author:GespachCClld:pubmed
pubmed-article:3018694pubmed:issnTypePrintlld:pubmed
pubmed-article:3018694pubmed:volume7 Suppl 1lld:pubmed
pubmed-article:3018694pubmed:ownerNLMlld:pubmed
pubmed-article:3018694pubmed:authorsCompleteYlld:pubmed
pubmed-article:3018694pubmed:pagination155-63lld:pubmed
pubmed-article:3018694pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:meshHeadingpubmed-meshheading:3018694-...lld:pubmed
pubmed-article:3018694pubmed:year1986lld:pubmed
pubmed-article:3018694pubmed:articleTitleSecretin receptor activity in rat gastric glands. Binding studies, cAMP generation and pharmacology.lld:pubmed
pubmed-article:3018694pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3018694pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3018694lld:pubmed